Here is a latest new release from Imutec Pharma Inc.
IMT is on a final clinical phase of Virulizin drug. If the results
turn out to be promising IMT will be at least a $10 stock as predicted
by many biotech analysts.
Imutec Pharma Inc.
IMT TSE
March 6, 1997
Appointment of New Vice President, Clinical and Medical Affairs
TORONTO, March 6 /CNW/ - Imutec Pharma Inc. today announced the appointment of Guy Ely, M.D. as Vice President, Clinical and Medical Affairs of the Company.
Dr. Ely brings extensive clinical research and regulatory expertise to Imutec Pharma, having spent the past twelve years in the drug development business. He joins Imutec Pharma from SmithKline Beecham, where he most recently served as the Associate Medical Director of the Canadian subsidiary company. At SmithKline Beecham, Dr. Ely was responsible for the supervision of over 50 clinical trials for the three major corporate divisions, 90% of which were international studies.
Prior to his tenure at SmithKline Beecham, Dr. Ely was Vice President, Clinical and Medical Affairs at BioChem Therapeutic Inc., a wholly owned subsidiary of BioChem Pharma Inc. At BioChem Therapeutic, Dr. Ely established and supervised the International Medical Department for the BioChem group of companies; an internal division that coordinated the medical, clinical and regulatory activities of the Pharmaceutical, Vaccine and Diagnostic divisions of BioChem Pharma. Among his numerous responsibilities, Dr. Ely was responsible for the coordination of all communication with Canadian and foreign regulatory agencies, as well as with BioChem's largest strategic partner, GlaxoWellcome.
Prior to joining BioChem Therapeutic, Dr. Ely was the Director of Clinical Research at Abbott Laboratories. At Abbott, Dr. Ely was responsible for the clinical, research and development activities of the company in Canada. Before joining Abbott Laboratories, Dr. Ely was the Manager, Clinical Investigation at Ciba-Geigy Canada.
Dr. Ely received his Doctorate of Medicine (M.D.) in 1979, when he graduated from the University of Paris. While in Paris, Dr. Ely received additional training in biochemistry and cardiology. He is currently a member of several professional associations, including the American Society of Clinical Oncology (ASCO), the Ontario Medical Association (OMA) and the Pharmaceutical Manufacturers Association of Canada (PMAC).
``We are extremely pleased that Dr. Ely has joined the new medical and scientific team at Imutec Pharma,'' said Philippe G. Lacaille, President and Chief Executive Officer at the Company. ``During the past decade, Dr. Ely has had the opportunity to gain a broad perspective of the medical, clinical and regulatory issues which affect biopharmaceutical companies like Imutec Pharma. In addition, through his work with the larger pharmaceutical companies, he has developed an in-depth knowledge of the issues that are important to our potential partners. This type of relevant experience is extremely important, and will serve the Company well, now, and in the future.''
``I am very excited to be joining Imutec Pharma at this time,'' said Dr. Ely. ``The Company has taken remarkable steps in building a very strong scientific and management team over a relatively short period of time. I am looking forward to working with the new team IN THE FINAL CLINICAL development of Virulizin(R), and in initiating the development of new products and technologies.''
Imutec Pharma is currently conducting a Phase I/II clinical trial of Virulizin(R) in the United States in the treatment of pancreatic adenocarcinoma. The Company is also conducting a Phase I/II clinical trial of Virulizin(R) in Canada in the treatment of advanced Kaposi's sarcoma in patients infected with the human immunodeficiency virus (HIV). In November 1996, the Company submitted an application for marketing approval of Virulizin(R) with the SSA (Ministry of Health, Mexico) for the treatment of advanced malignant melanoma.
Imutec Pharma is a biopharmaceutical company engaged in the development, manufacturing and commercialization of human therapeutic products targeted for use in the treatment of cancer and other diseases associated with immune system disorders.
Imutec Pharma's press releases are available through the Company's Internet site: imutec.com.
For further information: Wayne D. Cockburn, Vice President, Corporate Development, Tel: (416) 724-1100, ext. 269
This release processed by Canstock at 7:14:12 Pacific Time |
